Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired immune deficiency syndrome.
Ann Allergy Asthma Immunol. 1996 Nov;77(5):394-400. Unique Identifier : AIDSLINE MED/97087839 Kalanadhabhatta V; Muppidi D; Sahni H; Robles A; Kramer M; Division of Allergy/Clinical Immunology, Department of Medicine,; Medicine State University of New York, Health Science Center at; Brooklyn, USA.
Abstract:
OBJECTIVE: To study the outcome of a modified oral desensitization protocol for trimethoprim-sulfamethoxazole in human immunodeficiency virus infected patients with Pneumocystis carinii pneumonia and acquired immune deficiency syndrome. DESIGN: A prospective study. SETTING: Tertiary care referral center. PATIENTS: Thirteen human immunodeficiency virus infected patients with Pneumocystis carinii pneumonia and allergy to sulfonamides who failed alternative therapy. INTERVENTION: Oral desensitization to trimethoprim-sulfamethoxazole. MEASUREMENTS: Nature of allergic reactions, toxicity of alternate medications, indication as well as outcome of trimethoprim-sulfamethoxazole desensitization and routine laboratory determinations. RESULTS: The most common reaction to trimethoprim-sulfamethoxazole was generalized, pruritic maculopapular rash (n = 10, 76.9%) followed by urticaria/angioedema in two patients (15.38%). Two patients had generalized pruritus without rash. All patients (n = 13) tolerated oral desensitization to trimethoprim-sulfamethoxazole without any adverse reactions including three patients who were critically ill and on mechanical ventilation. Thus the success rate of our protocol was 100%. No patient had received antihistamines prior to or during the protocol. Four patients (5, 6, 7, and 9) were receiving prednisone for severe Pneumocystis carinii pneumonia. Total followup has ranged from 4 to 84 weeks. Two patients died during followup due to causes unrelated to desensitization. All other patients are tolerating trimethoprim-sulfamethoxazole without any allergic reactions. CONCLUSIONS: Oral desensitization to trimethoprim-sulfamethoxazole, as per this protocol is safe, in that there were no systemic or cutaneous reactions during desensitization as well as followup. It is well tolerated in all patients, including the three critically ill patients. As judged by the outcome and ability to tolerate trimethoprim-sulfamethoxazole after desensitization, the procedure is successful in all patients in this study. Equipped with this protocol one can evaluate possible mechanisms of desensitization such as oral tolerance or mediator depletion in a controlled fashion.
Keywords: Administration, Oral Adult Anaphylaxis/CHEMICALLY INDUCED AIDS-Related Opportunistic Infections/*DRUG THERAPY Desensitization, Immunologic/*METHODS Drug Hypersensitivity/*DRUG THERAPY/ETIOLOGY Female Human Male Middle Age Pneumonia, Pneumocystis carinii/*DRUG THERAPY Prospective Studies Treatment Outcome Trimethoprim-Sulfamethoxazole Combination/ADVERSE EFFECTS/ *THERAPEUTIC USE JOURNAL ARTICLE 970228
M9721164
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
